RT Journal Article
T1 Omalizumab: what benefits should we expect?
A1 Giménez-Arnau, Ana
A1 Velasco, Manel
A1 Armario Hita, Jose Carlos
A1 Labrador-Horrillo, Moises
A1 Silvestre Salvador, Juan Francisco
K1 chronic urticaria
K1 efficacy
K1 health care
K1 omalizumab
K1 safety
AB Chronic spontaneous urticaria (CSU) is a skin disease characterised by wheal appearance, swelling, itching, and painful skin. Omalizumab has been used for CSU treatment demonstrating good efficacy. To investigate the efficacy and safety of omalizumab treatment in CSU patients in real-life practice. A retrospective analysis was performed on 38 patients suffering from CSU who received 300 mg of omalizumab every four weeks. After omalizumab treatment, 68.4% of patients showed a complete response (UAS7 = 0). All the patients were able to stop treatment with corticosteroids, cyclosporine, and anti-leukotrienes, and only 39.5% of patients remained on anti-histamines. Omalizumab treatment led to a 96% and 65% decrease in emergency room and primary health care visits, respectively, as well as a reduction in the direct costs associated with the disease. No omalizumab-related adverse events were reported. Omalizumab exhibits good efficacy in alleviating the symptoms of CSU, leads to a decrease in concomitant medication use, restores patients' quality of life, and has economic benefits by reducing disease-related health care costs.
YR 2016
FD 2016
LK http://hdl.handle.net/10668/10114
UL http://hdl.handle.net/10668/10114
LA en
DS RISalud
RD Apr 4, 2025